XCell Therapeutics Inc is a Korea-based company primarily engaged in the manufacture and distribution of cell culture mediums. The Company is mainly engaged in the provision of dermal papilla cells (DPC), keratinocytes, exosomes and other dedicated mediums. Additionally, the Company is engaged in the manufacture and distribution of virus transport mediums. The Company sells its products in domestic and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
29/07/26	₩1,094.00	-2.50%	84,396
28/07/26	₩1,122.00	-5.08%	92,458
27/07/26	₩1,182.00	+0.17%	18,368
24/07/26	₩1,180.00	-1.58%	12,659
23/07/26	₩1,199.00	+2.92%	16,031

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 29/07/2026			5-day change	1st Jan Change
1,094.00 ^KRW	-2.50%		-6.09%	-34.14%

14/08/25	Xcell Therapeutics to conduct capital increase of 15 billion won	RE
22/11/24	Gencurix Inc. announced that it expects to receive KRW 899.999158 million in funding from Xcell Therapeutics Inc.	CI

Market Cap	18.92B 13.04M 11.46M 10.7M 9.82M 18.37M 1.25B 18.83M 127M 49.6M 618M 48.96M 47.9M 2.14B	P/E 2024	-4.26x	P/E 2025	-1.77x
Enterprise Value	17.5B 12.06M 10.6M 9.89M 9.08M 17M 1.16B 17.41M 117M 45.88M 572M 45.29M 44.3M 1.98B	EV / Sales 2024	21.3x	EV / Sales 2025	14x
Free-Float	88.23%	Yield 2024 *	-	Yield 2025	-

14/08/25	Xcell Therapeutics to conduct capital increase of 15 billion won	RE
22/11/24	Gencurix Inc. announced that it expects to receive KRW 899.999158 million in funding from Xcell Therapeutics Inc.	CI
16/07/24	Xcell Therapeutics Shares Fall 4.7% Below Offering Price on Kosdaq Debut	MT
08/07/24	Xcell Therapeutics Inc. has completed an IPO in the amount of KRW 16.18 billion.	CI

1 day	-2.50%
1 week	-6.09%
Current month	-8.91%
1 month	-10.69%
3 months	-38.30%
6 months	-31.41%
Current year	-34.14%

Xcell Therapeutics Inc. Stock

Stocks

A373110

KR7373110006

Pharmaceuticals

Valuation: Xcell Therapeutics Inc.

Chart: Xcell Therapeutics Inc.

Latest news : Xcell Therapeutics Inc.

News in other languages: Xcell Therapeutics Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Xcell Therapeutics Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	1,009	1,215
1 month	1,009	1,280
Current year	1,009	2,050
1 year	1,009	4,075
3 years	1,009	12,900
5 years	1,009	12,900
10 years	1,009	12,900

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
XCELL THERAPEUTICS INC.	-2.50%	-6.09%	-67.44%	-	13.04M
ELI LILLY AND COMPANY	-0.87%	+4.04%	+58.60%	+163.92%	1,079B
JOHNSON & JOHNSON	-0.45%	+3.87%	+57.95%	+52.18%	640B
ABBVIE INC.	+0.04%	+3.95%	+37.69%	+74.54%	465B
ROCHE HOLDING AG	-1.96%	+1.63%	+36.83%	+31.26%	353B
NOVARTIS AG	-1.56%	+0.19%	+34.60%	+40.44%	301B
ASTRAZENECA PLC	-2.09%	+1.56%	+12.07%	+15.20%	271B
NOVO NORDISK A/S	-1.58%	+4.09%	+2.58%	-38.95%	228B
AMGEN INC.	-1.39%	+5.90%	+27.70%	+64.00%	209B
GILEAD SCIENCES, INC.	-1.18%	+1.83%	+16.20%	+72.69%	165B
Average	-1.44%	+3.47%	+21.68%	+52.81%	370.97B
Weighted average by Cap.	-1.20%	+4.86%	+41.39%	+77.84%

	2024	2025
Net sales	1.93B 1.33M 1.17M 1.09M 1M 1.88M 128M 1.92M 12.97M 5.07M 63.19M 5.01M 4.9M 218M	1.95B 1.34M 1.18M 1.1M 1.01M 1.89M 129M 1.94M 13.06M 5.11M 63.67M 5.04M 4.93M 220M
Net income	-9.54B -6.58M -5.78M -5.39M -4.95M -9.27M -630M -9.5M -63.97M -25.02M -312M -24.69M -24.16M -1.08B	-10.93B -7.53M -6.62M -6.18M -5.67M -10.61M -721M -10.87M -73.25M -28.65M -357M -28.28M -27.66M -1.23B
Net Debt	-3.1B -2.14M -1.88M -1.75M -1.61M -3.01M -205M -3.09M -20.78M -8.13M -101M -8.02M -7.85M -350M	-1.42B -978K -860K -802K -736K -1.38M -93.7M -1.41M -9.51M -3.72M -46.37M -3.67M -3.59M -160M